Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against ...
No company financial data available. DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results